Citations

Clear

367 citation(s) found for "Su, Pan".

Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study
Yaghi, Shadi, Shu, Liqi , Mandel, Daniel , Henninger, Nils , Muppa, Jayachandra , Affan, Muhammad , Lodhi, Omair ul haq , Heldner, Mirjam R. , Seiffge, David , Omran, Setareh Salehi , Crandall, Ross , Lester, Evan, Mena, Diego López, Araúz, Antonio , Nehme, Ahmad , Boulanger, Marion , Sousa, João André , Sargento‐Freitas, João , Barata, Vasco , Castro‐Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Mallick, Dania, Rothstein, Aaron , Khazaal, Ossama , Kaufmann, Josefin E. , Engelter, Stefan T. , Traenka, Christopher , Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Zhou, Lily , Gandhi, Preet , Field, Thalia S. , Mancini, Steven, Metanis, Issa , Pan, Kelly , Dantu, Vishnu , Baumgartner, Karl , Nolte, Christian H. , Choi, Richard , MacDonald, Jason , Shahripour, Reza Bavarsad , Ghannam, Malik , Almajali, Mohammad , Sanchez, Sebastian , Zine-Eddine, Fayçal, Poppe, Alexandre Y. , Fonseca, Ana Catarina , Baptista, Maria Fortuna , Cruz, Diana , Marco, Giovanna De , Griffin, Kim, Kuohn, Lindsey , Frontera, Jennifer , Amar, Jordan , Giles, James , Grisendi, Ilaria , Nzwalo, Hipólito , Liebeskind, David S. , Molaie, Amir , Cavalier, Annie, Kam, Wayneho , Grory, Brian Mac , Kasab, Sami Al , Eltatawy, Ali , Chervak, Lina , Chulluncuy‐Rivas, Roberto, Aziz, Yasmin , Bakradze, Ekaterina , Tran, Thanh Lam , Rodrigo‐Gisbert, Marc , Velez, Faddi Saleh, Gracia, Jorge Ortiz, Mudassani, Varsha, Vishnu, Venugopalan Y. , Yaddanapudi, Sridhara , Adams, L, Browngoehl, Abigail, Ranasinghe, Tamra , Dunston, Randy, Lynch, Zachary, Penckofer, Mary , Mayer, Silvia, Zubair, Adeel , Cheng, Yee Kuang, Ferreira, Vítor Mendes , Asad, Syed Daniyal , Sarwat, Zoha, Balabhadra, Anvesh , Patel, Shivam , Secchi, Thaís , Mantovani, Gabriel, Kim, Young Dae , Krishnaiah, Balaji , Elangovan, Cheran , Lingam, Sivani, Quereshi, Abid, Alvarado, Alonso, Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria, Vassilopoulou, Sofia , Tentolouris, Vasilis, Martínez-Marino, Manuel , Wall, Victor Carrasco , Indraswari, Fransisca , Jamal, Sleiman El , Alvi, Muhammad , Sarvath, Mohammed, Kass‐Hout, Tareq , Shi, Feina , Zhang, Jinhua , Said, Jamil , Sen, Shayak, Ghani, Mohammad R , Elnazeir, Marwa , Xiao, Han , Kala, Narendra , Khan, Farhan , Mohammadzadeh, Nahid , Furie, Karen L. , Alvarado‐Bolaños, Alonso , Tentolouris-Piperas, Vasileios , Leon Guerrero, Christopher R , Henninger, Nils , Muppa, Jayachandra , Heldner, Mirjam R , Liebeskind, David S. , Field, Thalia S , Keser, Zafer , Aziz, Yasmin , Mandel, Daniel M , Seiffge, David , Arauz, Antonio , Sousa, Joao Andre , Sargento-Freitas, Joao , Castro-Chaves, Paulo , Kaufman, Josefin E , Engelter, Stefan T , Aguiar de Sousa, Diana , Soares, Mafalda , Rosa, Sara , Metanis, Issa , Nolte, Christian H , Bavarsad Shahripour, Reza , Almajali, Mohammad , Fonseca, Ana Catarina , Kuohn, Lindsey , Frontera, Jennifer , Giles, James , Nzwalo, Hipolito , Mac Grory, Brian , Eltatawy, Ali , Rodrigo Gisbert, Marc , Vishnu, Venugopalan Y , Ranasinghe, Tamra , Mendes Ferreira, Vítor , Kim, Young Dae , Elangovan, Cheran , Alvarado-Bolanos, Alonso , Khasiyev, Farid , Tentolouris-Piperas, Vasileios , Martinez Marino, Manuel , Ghani, Mohammad , Xiao, Han , Khan, Farhan , Nehme, Ahmad , Yaghi, Shadi , Antonenko, Kateryna , Arnold, Marcel , Touzé, Emmanuel , Leker, Ronen R , Burton, Tina , von Rennenberg, Regina , MacDonald, Jason, Guo, Xiaofan , Samaniego, Edgar A , Rioux, Bastien , Cruz, Diana , Romoli, Michele , Longoni, Marco , Keser, Zafer , Zedde, Marialuisa , Pascarella, Rosario , Anadani, Mohammad , Kicielinski, Kimberly , Requena, Manuel , Velez, Faddi G. Saleh , Havenon, Adam de , Siegler, James E. , Willey, Joshua , Sharma, Richa , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Martins, Sheila , Fridman, Sebastian , Liu, Shilin , Ali, Farman, Morsi, Rami Z. , Sokhi, Dilraj , Simpkins, Alexis N. , Gomez, Roberto, Sen, Shayak, Stretz, Christoph , Goldstein, Eric

Mayo Clinic

Stroke | June 4, 2025 | Volume: 55 | Issue: 4 | Pages: 908-918

10.1161/strokeaha.123.045731 | PMID 38335240 Get It

BACKGROUND: Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation. METHODS: This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma. The exposure was antithrombotic treatment type (anticoagulation versus antiplatelets), and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with inverse probability of treatment weighting to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an as-treated crossover approach and only included outcomes occurring with the above treatments. RESULTS: The study included 3636 patients (402 [11.1%] received exclusively anticoagulation and 2453 [67.5%] received exclusively antiplatelets). By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45–1.12]; P =0.145) and by day 180 (adjusted HR, 0.80 [95% CI, 0.28–2.24]; P =0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR, 1.39 [95% CI, 0.35–5.45]; P =0.637) but was by day 180 (adjusted HR, 5.56 [95% CI, 1.53–20.13]; P =0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR, 0.40 [95% CI, 0.18–0.88]; P interaction =0.009). CONCLUSIONS: Our study does not rule out the benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.
Multi-center evaluation of radiomics and deep learning to stratify malignancy risk of IPMNs
Bejar, Andrea Mia, Gonzalez, Maria , Hong, Ziliang , Aktas, Halil Ertugrul , Zhang, Zheyuan , Pan, Hongyi, Jozwiak, Zeynep Sue, Bol, Fergan , Zhao, Lili , Kartal, Gulbiz Dagoglu, Agarunov, Emil, Bruno, Marco J. , Huang, Chenchang, Gonda, Tamas A. , Bolan, Candice W. , Keswani, Rajesh N. , Tiwari, Pallavi , Bolan, Candice, Gonzalez, María Jaramillo, Durak, Görkem , Keleş, Elif , Pan, Hongyi , Jozwiak, Zeynep Sue, Chen, Chao , Spampinato, Concetto , Medetalibeyoğlu, Alpay , Ertürk, Şükrü Mehmet , Velichko, Yury , Xu, Ziyue , Jambawalikar, Sachin , Schoots, Ivo G. , Huang, Chenchang, Miller, Frank H. , Wallace, Michael B. , Tiwari, Pallavi , Bağcı, Ulaş

Mayo Clinic

No container title available | May 30, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6622868/v1 | PMID 40502758 Get It

Abstract Distinguishing high-risk intraductal papillary mucinous neoplasms (IPMNs), pancreatic cysts requiring surgery, from low-risk lesions remains a clinical challenge, often resulting in unnecessary procedures due to limited specificity of current methods. While radiomics and deep learning (DL) have been explored for pancreatic cancer, cyst-level malignancy risk stratification of IPMNs remains untapped. We conducted a multi-institutional study (seven centers, 359 T2W MRI images) to assess the feasibility of AI for predicting IPMN dysplasia grade using cyst-level image features. We developed and compared 2D and 3D radiomics-only, deep learning (DL)-only, and radiomics-DL fusion models, using expert radiologist scoring as a baseline reference. Model performance was evaluated using held-out test data. The radiomics-DL fusion model showed the highest discriminatory ability on the test set (AUC 0.692), outperforming the radiomics-only model (AUC 0.665). Expert accuracy varied widely (37.4%-66.7%). The fusion model integrating deep learning and radiomics features from routine T2W MRI (AUC: 0.692) demonstrates potential for objective, cyst-level risk stratification of IPMNs in a multi-center cohort, outperforming both radiomics-only models and expert radiologists. While performance requires improvement for standalone clinical use, this approach offers a scalable, non-invasive method to potentially improve diagnostic accuracy and reduce unnecessary surgical interventions.
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).
Levy, Benjamin , Paz‐Ares, Luis , Herbert, Scott M., Yang, Tsung‐Ying , Lou, Yanyan , Zenke, Yoshitaka , Dómine, Manuel , Leventakos, Konstantinos , Horiike, Atsushi , Jia, Xiaoyu , Chiaverelli, Rachel, Goto, Yasushi , Lin, Chien‐Chung , Tolcher, Anthony W. , Cortinovis, Diego Luigi , Felip, Enriqueta , Calvo, Emiliano , Pan, Edward , Matsubara, Keisuke , Chisamore, Michael Jon

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 8501-8501

10.1200/jco.2025.43.16_suppl.8501 Get It

8501 Background: TROPION-Lung02 (NCT04526691) evaluated the TROP2-directed antibody-drug conjugate (ADC) Dato-DXd plus pembro combination with or without Pt-CT in aNSCLC. Here we report primary analyses of pts receiving combination therapy in the 1L setting. Methods: Pts across 6 cohorts were dosed with Dato-DXd (4 or 6 mg/kg) plus pembro 200 mg alone (doublet) or with pembro plus Pt-CT (triplet; cisplatin 75 mg/m 2 or carboplatin AUC 5) Q3W. PD-L1 expression (tumor proportion score) was assessed locally by immunohistochemistry (22C3 assay). Primary objectives were safety and tolerability; efficacy was a secondary objective. Results: As of Apr 29, 2024, 96 pts received either the doublet (n=42) or triplet (n=54) combination as 1L therapy; 29% and 15% of pts were ongoing, respectively. Median ages were 65 (doublet) and 64 years (triplet). Median treatment durations were 9.7 and 5.8 months, respectively. Stomatitis (doublet, 57%; triplet, 33%) and nausea (doublet, 42%; triplet, 48%), primarily Gr 1–2, were the most common adverse events (AEs) across both regimens. Treatment related serious AEs occurred in 5 (12%) and 12 (22%) pts in each cohort and no deaths related to study drug were seen. Efficacy outcomes, including by histology, are summarized in the Table. Biomarker analyses, including efficacy by PD-L1 status, will be presented. Conclusions: In this largest data set to date evaluating an ADC combined with an anti-PD-1/L1 agent in the 1L setting, the combination of Dato-DXd plus pembro treatment both with and without Pt-CT elicited durable antitumor activity in pts with aNSCLC. Tolerability of the combinations was as expected, based on known profiles of the individual agents. Clinical trial information: NCT04526691 . All 1L (n=96) 1L, Nonsquamous (n=75) 1L, Squamous (n=21) Response, n (%) Doublet (n=42) Triplet (n=54) Doublet (n=33) Triplet (n=42) Doublet (n=9) Triplet (n=12) Confirmed objective response rate 23 (55) 30 (56) 17 (52) 24 (57) 6 (67) 6 (50) Complete response 1 (2) 2 (4) 1 (3) 2 (5) 0 0 Partial response 22 (52) 28 (52) 16 (49) 22 (52) 6 (67) 6 (50) Stable disease 14 (33) 18 (33) 12 (36) 14 (33) 2 (22) 4 (33) Progressive disease 3 (7) 2 (4) 3 (9) 1 (2) 0 1 (8) Disease control rate a 37 (88) 48 (89) 29 (88) 38 (91) 8 (89) 10 (83) Median duration of response, mo (95% CI) 20.1 (9.7–NE) 13.7 (5.7–NE) 24.9 (9.7–NE) 18.0 (8.0–NE) 12.0 (5.5–NE) 5.5 (4.1–NE) Median PFS, mo (95% CI) 11.2 b (8.2–21.3) 6.8 c (5.5–11.1) 11.2 (6.1–21.3) 10.8 (5.5–17.3) 10.2 (0.4–NE) 6.7 (1.0–8.2) a Proportion of pts with confirmed CR + PR + SD at 12 wks. b.c Median (95% CI) PFS follow-up, mo: b 17.3 (11.3−26.8); c 23.5 (17.3−27.9). mo, months; NE, not evaluable.
Alternating 2D and 3D Culture Reduces Cell Size and Extends the Lifespan of Placenta-Derived MSCs
Pan, Ying , Li, Han , Yang, Yakun , Wang, Aijun , Zhu, Wuqiang , Wang, Shue , Wang, Aijun , Wang, Shue , Zhu, Wuqiang , Wu, Xinran , Xie, Liangqi , Lei, Yuguo

Mayo Clinic

No container title available | May 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.20.655182 | PMID 40475514 Get It

Abstract Mesenchymal stem cells (MSCs) offer significant therapeutic potential, but traditional 2D culture on rigid substrates results in progressive cell enlargement and senescence, reducing proliferative capacity and therapeutic potency. This poses a major challenge for widespread clinical application. We explored a novel strategy for placenta-derived MSCs combining 2D expansion with 3D spheroid culture to address these limitations. Our research shows that culturing MSCs as 3D spheroids significantly reduces individual cell size and size distribution compared to 2D culture. Spheroid formation is feasible in chemically defined media with minimal cell death, and is enhanced by extracellular matrix protein supplementation. Although MSCs do not proliferate in 3D suspension, an alternating 2D/3D culture protocol, transitioning cells between 2D flasks and 3D spheroids after each passage, effectively slows MSC enlargement and senescence over long periods. This alternating method also preserves MSC immunomodulatory function, unlike continuous 2D culture which leads to its loss. For scalability, we developed an RGD-functionalized alginate hydrogel tube (AlgTube) system that mimics this alternating environment, supporting both adherent growth and chemically triggered spheroid formation. This alternating 2D/3D culture strategy and the scalable AlgTube platform provide a foundation for developing next-generation MSC manufacturing technologies to meet future clinical demands.
Adaptive Aggregation Weights for Federated Segmentation of Pancreas MRI
Pan, Hongyi , Zhang, Zheyuan , Taktak, Yavuz , Keleş, Elif , Aktas, Halil Ertugrul , Velichko, Yury , Schoots, Ivo G. , Bruno, Marco J. , Keswani, Rajesh N. , Bolan, Candice W. , Gonda, Tamas A. , GORRins, Michael G., Velichko, Yuri S , Durak, Görkem , Medetalibeyoğlu, Alpay , Spampinato, Concetto , Tiwari, Pallavi , Wallace, Michael B. , Xu, Ziyue , Bağcı, Ulaş

Mayo Clinic

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10981148 Get It

IPMN Risk Assessment Under Federated Learning Paradigm
Pan, Hongyi , Hong, Ziliang , Keleş, Elif , Aktas, Halil Ertugrul , Taktak, Yavuz , Medetalibeyoğlu, Alpay , Zhang, Zheyuan , Velichko, Yury , Schoots, Ivo G. , Bruno, Marco J. , Tiwari, Pallavi , Bolan, Candice W. , Gonda, Tamas A. , Miller, Frank, Keswani, Rajesh N. , Miller, Frank H. , Miller, Frank H , Velichko, Yuri S , Durak, Görkem , Spampinato, Concetto , Tiwari, Pallavi , Wallace, Michael B. , Xu, Ziyue , Bağcı, Ulaş

Mayo Clinic

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10980733 Get It

Concurrent or subsequent lymphomatous effusion in large B-cell lymphoma portends a dismal prognosis: A multi-institutional study
Tang, Haiming , Xu, Jie , McCracken, Jenna , Li, Peng , Braunberger, Ryan C. , Wu, Xiaojun , Wang, Endi , Zhang, Qianyun , Soma, Lorinda, Zhang, Jingjing , Matsumoto, Nana , Xu, Mina L. , Pan, Zenggang , Tang, Haiming , Wang, Endi , Katz, Samuel G , Zhang, Jing Jing , Pan, Zenggang , Gisriel, Savanah D. , Ji, Yuan , Fang, Hong , Li, Shaoying , Xu‐Monette, Zijun Y. , Young, Ken H.

Mayo Clinic

American Journal of Clinical Pathology | May 9, 2025 | Volume: 164 | Issue: 3 | Pages: 390-401

10.1093/ajcp/aqaf057 | PMID 40581918 Get It

Abstract Objective Rare large B-cell lymphomas (LBCLs) present with concurrent or subsequent lymphomatous effusion (solid-effusion LBCL, SE-LBCL), which may have an inferior prognosis compared with their noneffusion counterpart. In addition, the relationship between SE-LBCL and human herpesvirus 8–negative effusion-based LBCL (EB-LBCL) remains unclear. Methods We collected 141 cases of SE-LBCL and a control cohort of 101 cases of stage IV solid-only LBCL. The clinicopathologic features were analyzed and compared between SE-LBCL and solid-only LBCL. Results Patients with SE-LBCL had a median age of 67 years with a male-to-female ratio of 1.3:1. Eighty-six patients had concurrent solid lymphoma and lymphomatous effusion, whereas 55 developed lymphomatous effusion subsequently. Most cases involved the pleural cavities (79%, 112/141), followed by the peritoneal (21%, 29/141) and pericardial (11%, 16/141) cavities. BCL6, CD10, and MUM1 were expressed in 77% (90/117), 46% (60/130), and 61% (58/95) of cases, respectively, and 58% (71/123) were subclassified into the germinal center B-cell (GCB) subtype. Rearrangements of BCL2, BCL6, and MYC were detected in 42% (31/73), 35% (22/63), and 40% (35/88), respectively, and 22% (19/87) had both MYC and BCL2 rearrangements. The patients with SE-LBCL had a dismal prognosis, with a median survival of 5.7 months, which was significantly worse than solid-only LBCL (147.5 months; P < .0001). Conclusions The pathologic features of SE-LBCL were similar to those of solid-only LBCL but distinct from those of EB-LBCL; in particular, lymphomatous effusion was an independently adverse prognostic factor in LBCL. Our study underscores the need for surveillance of lymphomatous effusion during LBCL staging and development of effective therapeutic regimens for SE-LBCL.
A human and mouse subpopulation of senescent β-cells induces pathologic dysfunction through targetable paracrine signaling
Carapeto, Priscila , Abarca, Cristian , Hela, Francesko , Sanjines, Stephanie, Pena, Sebastian, Le, Sandra M., Cahill, Christopher, Midha, Ayush , Baker, Dylan , Espinoza, Sara , Cigarroa, Francisco , Woolworth, Jillian L., Kirkland, James L. , Musi, Nicolas , Aguayo‐Mazzucato, Cristina , Iwasaki, Kanako , Carapeto, Priscila , Abarca, Cristian , Hela, Francesko , Midha, Ayush , Domanskyi, Sergii , Chuang, Jeffrey H , Kuchel, George A , Robson, Paul , Aguayo-Mazzucato, Cristina , Pena, Alejandro , Iwasaki, Kanako , Pena, Sebastian, Pan, Hui , Alcoforado Diniz, Juliana , Domanskyi, Sergii , Espinoza, Sara, Pena, Alejandro, Garovic, Vesna D. , Tchkonia, Tamar , Kuchel, George A. , Robson, Paul

Mayo Clinic

No container title available | May 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.07.648438 | PMID 40654723 Get It

ABSTRACT Cellular senescence is a stress response mechanism marked by irreversible growth arrest, upregulation of antiapoptotic pathways, loss of cellular function, and remodelling of the cellular secretory profile. In both humans and mice, pancreatic β-cells undergo senescence with age and insulin resistance. Targeted removal of senescent cells in mouse models of diabetes improves glucose homeostasis, demonstrating the role β-cell senescence in diabetes progression. In contrast, β-cell senescence also promotes immune surveillance, promoting β-cell survival and function. Thus, a better understanding of senescent cells’ phenotypic and functional heterogeneity is needed to develop effective therapeutic strategies. Herein, we show that subpopulations of senescent β-cells in mice and humans, which were identified through the expression of Cdkn1a (encoding p21 Cip1 ) and Cdkn2a (encoding p16 Ink4a ) by single-cell RNA sequencing (scRNA-seq), flow cytometry, spatial transcriptomics, and spatial proteomics, exhibit distinct transcriptional and functional identities. The predominant senescent β-cell subpopulation expressed Cdkn1a and was characterized by a lack of glucose responsiveness, high basal insulin secretion, and transcription of canonical SASP factors. The SASP of Cdkn1a -expressing β-cells had non-cell autonomous effects on neighbouring cells. A subset of four SASP factors from Cdkn1a + cells was sufficient to induce secondary senescence and β-cell dysfunction in vitro . JAK inhibitors (JAK1/2 and JAK1/3) counteracted secondary senescence induction and restored β-cell function in high-fat diet-fed mice and human islets from donors with or without type 2 diabetes. GRAPHICAL ABSTRACT
Evidence-based guidelines for the pharmacological treatment of migraine, summary version
Ornello, Raffaele , Caponnetto, Valeria , Ahmed, Fayyaz , Al‐Khazali, Haidar M. , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia, Cevoli, Sabina , Cheng, Shuli, Chiarugi, Alberto , Christensen, Rune Häckert , Chu, Min Kyung , Crema, Santiago , Stefano, Vincenzo Di , Ekizoğlu, Esme , Fallacara, Adriana , Favoni, Valentina , Garces, Kimberly, Granato, Antonio, Granella, Franco, Ha, Woo‐Seok , Hirata, Koichi , Hoffmann, Jan , Hüssler, Eva-Maria, Hussein, Mona , Jenkins, Bronwyn , Labastida‐Ramírez, Alejandro , Laporta, Anna, Levin, Morris , Lupica, Antonino , Mampreso, Edoardo, Martinelli, Daniele , Orologio, Ilaria, Panneerchelvam, Lavindren Luke, Quattrocchi, Silvia, Romanenko, V.I. , Romozzi, Marina , Russo, Antonio , Sances, Grazia , Sarchielli, Paola , Silvestro, Marcello , Tassorelli, Cristina , Tessitore, Alessandro , Christensen, Rune H. , Ambrosini, Anna , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia , Casillo, Francesco , Cevoli, Sabina , Chiang, Chia-Chun , Chu, Min Kyung , Coppola, Gianluca , Corbelli, Ilenia , De Icco, Roberto , de Tommaso, Marina , Di Stefano, Vincenzo , Diener, Hans-Christoph , Ekizoglu, Esme , Fallacara, Adriana , Favoni, Valentina , Ha, Woo-Seok , Hassan, Amr , Hoffmann, Jan , Hussein, Mona , Iannone, Luigi Francesco , Martinelli, Daniele , Monteith, Teshamae S , Pan, Li-Ling Hope , Rozen, Todd D. , Souza, Marcio Nattan P , Pozo-Rosich, Patricia , Rainero, Innocenzo , Romanenko, Volodymyr , Romozzi, Marina , Russo, Antonio , Sances, Grazia , Schwedt, Todd J , Swerts, Diego Belandrino , Tassorelli, Cristina , Togha, Mansoureh , Vaghi, Gloria , Wang, Shuu-Jiun , Ashina, Messoud , Sacco, Simona , Ornello, Raffaele , Al-Khazali, Haidar M , Ahmed, Fayyaz , Brighina, Filippo , Calabresi, Paolo , Casillo, Francesco , Chiang, Chia‐Chun , Coppola, Gianluca , Lorenzo, Cherubino Di , Diener, Hans‐Christoph , Geppetti, Pierangelo , Goicochea, María Teresa , Guérzoni, Simona , Hassan, Amr , Huessler, Eva‐Maria , Monteith, Teshamae , Özge, Aynur , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Prudenzano, Maria Pia , Quattrocchi, Silvia, Rainero, Innocenzo , Romozzi, Marina , Schwedt, Todd J. , Tessitore, Alessandro , Wang, Shuu‐Jiun , Ashina, Messoud , Sacco, Simona

Mayo Clinic

Cephalalgia | April 25, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1177/03331024251321500 | PMID 40277321 Get It

We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the GRADE approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
Evidence-based guidelines for the pharmacological treatment of migraine
Ornello, Raffaele , Caponnetto, Valeria , Ahmed, Fayyaz , Al‐Khazali, Haidar M. , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia, Cevoli, Sabina , Cheng, Shuli, Chiarugi, Alberto , Christensen, Rune Häckert , Chu, Min Kyung , Crema, Santiago , Stefano, Vincenzo Di , Ekizoğlu, Esme , Fallacara, Adriana , Favoni, Valentina , Garces, Kimberly, Granato, Antonio, Granella, Franco, Ha, Woo‐Seok , Hirata, Koichi , Hoffmann, Jan , Hüssler, Eva-Maria, Hussein, Mona , Jenkins, Bronwyn , Labastida‐Ramírez, Alejandro , Laporta, Anna, Levin, Morris , Lupica, Antonino , Mampreso, Edoardo, Martinelli, Daniele , Orologio, Ilaria, Panneerchelvam, Lavindren Luke, Quattrocchi, Silvia, Romanenko, V.I. , Romozzi, Marina , Russo, Antonio , Sances, Grazia , Sarchielli, Paola , Silvestro, Marcello , Tassorelli, Cristina , Tessitore, Alessandro , Christensen, Rune H. , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia , Casillo, Francesco , Chiang, Chia-Chun , Chu, Min Kyung , Coppola, Gianluca , Corbelli, Ilenia , De Icco, Roberto , de Tommaso, Marina , Di Stefano, Vincenzo , Diener, Hans-Christoph , Favoni, Valentina , Ha, Woo-Seok , Hoffmann, Jan , Hussein, Mona , Iannone, Luigi Francesco , Martinelli, Daniele , Monteith, Teshamae S , Pan, Li-Ling Hope , Rozen, Todd D. , Souza, Marcio Nattan P , Pozo-Rosich, Patricia , Rainero, Innocenzo , Romozzi, Marina , Russo, Antonio , Schwedt, Todd J , Swerts, Diego Belandrino , Tassorelli, Cristina , Togha, Mansoureh , Vaghi, Gloria , Wang, Shuu-Jiun , Ornello, Raffaele , Al-Khazali, Haidar M , Ahmed, Fayyaz , Ambrosini, Anna , Brighina, Filippo , Calabresi, Paolo , Casillo, Francesco , Chiang, Chia‐Chun , Coppola, Gianluca , Lorenzo, Cherubino Di , Diener, Hans‐Christoph , Geppetti, Pierangelo , Goicochea, María Teresa , Guérzoni, Simona , Hassan, Amr , Huessler, Eva‐Maria , Monteith, Teshamae , Özge, Aynur , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Prudenzano, Maria Pia , Quattrocchi, Silvia, Rainero, Innocenzo , Romozzi, Marina , Schwedt, Todd J. , Tessitore, Alessandro , Wang, Shuu‐Jiun , Ashina, Messoud , Sacco, Simona

Mayo Clinic

Cephalalgia | April 25, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1177/03331024241305381 | PMID 40277319 Get It

We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the Grading of Recommendations, Assessment, Development and Evaluation approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.